By and thus the overall progression of Alzheimer’s disease can be reduced.
Alzheimer’s is a neurodegenerative disease that leads to cognitive decline and results in affected memory, reasoning. Subsequently, it can also impact the basic memory such as language as well as the thinking process of a person. Every year millions of people fall prey to this disease and it is currently one of the leading causes of fatalities in the United States.
A promising new approach to potentially treat Alzheimer’s disease – and also vaccinate against it – has been developed by scientists at @uniofleicester in collaboration with University Medical Center Göttingen and @lifearc1— University of Leicester (@uniofleicester) November 16, 2021
👉 https://t.co/WlwXpzaIEI pic.twitter.com/MYpumsCdo1
Although the quest to find the right and accurate answer to Alzheimer’s is still nowhere to be completed. But a recent collaboration between the University of Leicester in the UK and the University Medical Center Gottingen in Germany and Life Arch which is a medical charity has resulted in the production of two novel immunotherapies that can be finalized to stop the progression of this neurodegenerative disease.
Experts are firm that amyloid-beta is a protein that plays a crucial as well as causal role in the progression of Alzheimer’s. Further research has provided concrete evidence that there are certain variants of this disease that can prove to be more vital and fatal in the case of this disease.
According to Dr. Mark Carr who is the co-author of the study:
“We have identified the form of the amyloid-beta protein responsible for driving AD and have shown that specifically targeting this form of the protein in two mouse models of AD results in substantial improvements in key markers of disease progression.”
The monoclonal antibodies which are known as TAP01 can help in the treatment of this disease. On the other hand a vaccine has also been developed which will train our immune system to identify this protein and activate its defense mechanism.